ERBB3 and neoplasm: To determine if the effect of Mv-HER3-induced PAbs on these oncogenic receptors is traduced into an antitumor effect, we first evaluated their cytotoxic effect on several human tumor cell lines that express HER3, as well as HER1 and HER2 (including breast, prostate, and lung tumor cell lines).